Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 16/20 | 0.81 |
| ▸ | CA2 | P00918 | 7/20 | 0.81 |
| ▸ | CA9 | Q16790 | 6/20 | 0.81 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446846 | 0.90 | STS (1.00) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL14513805 | 0.90 | STS (1.00) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL13318875 | 0.90 | STS (1.00) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL29551370 | 0.90 | STS (1.00) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL10071070 | 0.90 | STS (1.00) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL14549386 | 0.90 | STS (1.00) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL1236145 | 0.89 | STS (0.78) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL13318877 | 0.89 | STS (0.91) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL4212435 | 0.87 | STS (0.80) | STSCA2CA9CA1CYP1A2 | |
| SCHEMBL4212438 | 0.87 | STS (0.80) | STSCA2CA9CA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893284-B2 | Oestrogen derivatives as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| EP-1608671-B1 | OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE | STERIX LTD (GB) | 2010-01-06 | — | — | EP | disclosed |
| US-20060094696-A1 | Oestrogen derivatives as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2006-05-04 | — | — | US | disclosed |
| EP-1608671-A1 | OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE | Sterix Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085459-A1 | OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE | STERIX LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094696-A1 | Oestrogen derivatives as inhibitors of steroid sulphatase | HSD17B11, ESRRA, ESRRB | STS 5/4885CA2 625/4885CA9 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.